Join Andrew Kennedy, Ph.D.Director of Business Development – Europe for his presentation on the optimization and manufacturing process of DOTAGA-Labeled Urea-Based Peptide PSMA Inhibitor. Peptide receptor radionuclide therapy (PRRT) is a targeted therapeutic strategy that uses peptides to deliver cytotoxic radiation levels to specific receptors overexpressed in cancer cells. Peptides are advantageous as therapeutic vectors in PRRT due to their small size, favorable pharmacokinetics, high binding affinity, low immunogenicity and toxicity, and minimal off-target binding. Tumor-targeting peptides conjugated [...]